Adamax Blood Work Labs Check Before After | Real Peptides

Adamax Blood Work Labs Check Before After | Real Peptides

Most peptide users don't fail because they chose the wrong compound. They fail because they never confirmed what their body needed in the first place. A comprehensive Adamax blood work labs check before starting any peptide protocol establishes your baseline metabolic, hormonal, and cardiovascular profile; the same panel repeated 8–12 weeks after starting treatment reveals whether the intervention is producing the intended physiological changes or triggering risks that symptom monitoring alone would miss. IGF-1 can climb into supraphysiological ranges without causing noticeable symptoms; liver enzymes can elevate silently; fasting glucose can drift upward while you feel fine.

Our team has reviewed protocols across hundreds of research applications. The pattern is consistent: pre- and post-intervention blood panels separate successful protocols from expensive guesswork.

What should Adamax blood work labs check before and after peptide use include?

Adamax blood work labs check before after should include a complete metabolic panel (CMP), lipid panel, complete blood count (CBC), thyroid function tests (TSH, Free T3, Free T4), hormone markers (total testosterone, free testosterone, estradiol, SHBG), IGF-1, fasting insulin, hemoglobin A1c, and liver enzymes (ALT, AST). Baseline testing identifies pre-existing contraindications; follow-up panels at 8–12 weeks reveal protocol efficacy and detect adverse trends before they become clinically significant.

The direct answer misses one critical nuance: most standard wellness panels don't measure IGF-1 or SHBG. Two of the most important markers for peptide monitoring. A "full metabolic panel" from a walk-in clinic often excludes the exact biomarkers that reveal whether growth hormone secretagogues like MK 677 or mitochondrial enhancers like Dihexa are producing their intended effects. This article covers exactly which biomarkers matter for peptide monitoring, what ranges indicate efficacy versus risk, and what follow-up timing catches problems early.

Why Baseline Blood Work Matters More Than You Think

Starting a peptide protocol without baseline labs is the equivalent of navigating without a map. You have no reference point to measure progress or detect deviation. Peptides influence multiple biological pathways simultaneously: growth hormone secretagogues elevate IGF-1 and can shift fasting glucose; thymic peptides like Thymalin modulate immune markers; neuropeptides like Cerebrolysin interact with neurotransmitter systems that blood tests can proxy through cortisol and thyroid function.

A pre-protocol panel establishes your individual normal ranges. IGF-1 reference ranges are age-adjusted, but individual variation within those ranges is substantial. Someone at the 25th percentile of normal may experience entirely different responses to growth hormone secretagogues than someone starting at the 75th percentile. Without knowing your baseline, you can't interpret whether a post-protocol IGF-1 of 220 ng/mL represents a therapeutic elevation or a supraphysiological spike.

Baseline testing also identifies absolute contraindications. Elevated liver enzymes (ALT >40 U/L, AST >35 U/L) suggest pre-existing hepatic stress that certain peptides could compound. Fasting glucose above 100 mg/dL or hemoglobin A1c above 5.7% indicates impaired glucose regulation. Growth hormone secretagogues can worsen insulin resistance in this context. Total testosterone below 300 ng/dL in men or thyroid dysfunction (TSH outside 0.5–2.5 mIU/L) means the endocrine system is already under strain; layering peptides on top without addressing root causes rarely produces optimal outcomes.

The Adamax Blood Work Labs Panel — What Gets Measured and Why

A comprehensive Adamax blood work labs check covers six core categories, each revealing distinct aspects of metabolic and hormonal function.

Metabolic Function (CMP): Includes electrolytes (sodium, potassium, chloride, bicarbonate), kidney markers (creatinine, BUN, eGFR), and liver enzymes (ALT, AST, ALP, bilirubin). Peptide protocols that influence hydration status, protein synthesis, or hepatic metabolism can shift these values. Creatinine often rises slightly with increased muscle mass; liver enzymes can elevate transiently during dose escalation.

Lipid Panel: Total cholesterol, LDL-C, HDL-C, triglycerides. Growth hormone and IGF-1 influence lipid metabolism. Supraphysiological IGF-1 levels can reduce LDL and raise HDL, which sounds beneficial but may mask underlying cardiovascular risk if the shift is too rapid.

Hormone Markers: Total testosterone, free testosterone, estradiol, SHBG (sex hormone-binding globulin), DHEA-S. Peptides that influence the hypothalamic-pituitary axis can suppress endogenous testosterone production or shift the testosterone-to-estradiol ratio. SHBG is particularly important. It binds testosterone and estradiol, so changes in SHBG alter bioavailable hormone levels even if total levels remain stable.

IGF-1 (Insulin-Like Growth Factor 1): The primary downstream marker of growth hormone activity. Normal ranges are age-adjusted: 115–358 ng/mL for adults 20–39 years, declining to 71–290 ng/mL for ages 60+. Growth hormone secretagogues like MK 677 typically elevate IGF-1 by 40–90% from baseline within 4–8 weeks at therapeutic doses.

Glucose Regulation: Fasting glucose, fasting insulin, hemoglobin A1c, HOMA-IR (calculated from glucose and insulin). Growth hormone and IGF-1 have complex effects on glucose homeostasis. Acute elevations improve insulin sensitivity, but chronic supraphysiological levels can induce insulin resistance. Monitoring all four markers reveals the net effect.

Thyroid Function: TSH, Free T3, Free T4, reverse T3. Thyroid hormones regulate basal metabolic rate and interact bidirectionally with growth hormone pathways. Subclinical hypothyroidism (TSH >2.5 mIU/L with normal T3/T4) blunts the response to growth hormone secretagogues and must be corrected before peptide protocols begin.

Adamax Blood Work Labs Check Before After — Comparison Table

This table shows how key biomarkers typically shift from baseline to 8–12 weeks post-protocol for common peptide categories, along with professional assessment criteria.

IGF-1 (ng/mL)

Age-adjusted normal (e.g., 150–250 for age 30–40)

40–90% elevation from baseline

↑

>400 ng/mL warrants dose reduction

Elevation confirms GH secretagogue efficacy; exceeding 400 ng/mL increases risk without added benefit

Fasting Glucose (mg/dL)

70–99 (normal)

Should remain <100

→ or slight ↑

≥100 mg/dL indicates impaired fasting glucose

GH can transiently raise glucose; sustained elevation requires protocol adjustment

ALT/AST (U/L)

<40 / <35 (normal)

Should remain within 10% of baseline

→

ALT >60 or AST >50 requires investigation

Transient elevation during dose escalation is common; sustained elevation suggests hepatic stress

Total Testosterone (ng/dL, males)

300–1000 (normal)

Should remain stable or increase slightly

→ or ↑

<300 ng/dL indicates suppression

Some peptides suppress endogenous production; significant drop requires intervention

SHBG (nmol/L)

10–57 (males), 18–114 (females)

Should remain stable

Significant deviation alters free hormone availability

Changes in SHBG affect bioavailable testosterone/estradiol even if total levels are stable

Hemoglobin A1c (%)

<5.7 (normal)

Should remain <5.7

≥5.7% indicates prediabetes

Long-term glucose control marker; more reliable than single fasting glucose tests

Key Takeaways

Baseline Adamax blood work labs establish individual normal ranges before peptide intervention, allowing accurate interpretation of post-protocol changes that generic reference ranges miss.

IGF-1 elevation of 40–90% from baseline within 8 weeks confirms growth hormone secretagogue efficacy, but levels above 400 ng/mL increase risk without added benefit.

Fasting glucose, fasting insulin, and hemoglobin A1c must be monitored together. Growth hormone can improve acute insulin sensitivity while worsening long-term glucose regulation if doses are excessive.

Liver enzymes (ALT, AST) often rise transiently during peptide dose escalation; sustained elevation above 60 U/L (ALT) or 50 U/L (AST) requires protocol adjustment or discontinuation.

SHBG (sex hormone-binding globulin) binds testosterone and estradiol. Changes in SHBG alter bioavailable hormone levels even when total testosterone remains stable, making it a critical monitoring marker.

Post-protocol testing at 8–12 weeks catches adverse trends (insulin resistance, hepatic stress, hormone suppression) before they become clinically significant or symptomatic.

What If: Adamax Blood Work Scenarios

What If My IGF-1 Doubles After Starting MK 677?

Reduce your dose by 30–50% and retest in 4 weeks. IGF-1 doubling from baseline (e.g., 180 ng/mL to 360 ng/mL) often occurs at doses above 20mg daily and increases risk of insulin resistance, joint pain, and carpal tunnel symptoms without proportional benefit. Most therapeutic effects plateau at IGF-1 elevations of 60–80% above baseline, corresponding to 12.5–15mg daily MK 677 for most users. Dose-response curves for growth hormone secretagogues are non-linear. Higher doses produce diminishing returns and disproportionate side effects.

What If My Fasting Glucose Rises to 105 mg/dL on a Peptide Protocol?

Suspend the protocol immediately and retest fasting glucose plus fasting insulin within one week. Fasting glucose above 100 mg/dL indicates impaired glucose regulation; if fasting insulin is also elevated (>10 μIU/mL), you're developing insulin resistance. Growth hormone and IGF-1 have biphasic effects on glucose metabolism. Therapeutic doses improve insulin sensitivity, but supraphysiological levels or prolonged use without dietary structure can induce compensatory hyperinsulinemia. Resume only after glucose normalizes and only at 50% of the previous dose with strict carbohydrate timing around training windows.

What If My Liver Enzymes Are Elevated Before I Even Start?

Do not begin any peptide protocol until liver function normalizes. ALT above 40 U/L or AST above 35 U/L suggests hepatic inflammation or fatty liver disease, both of which certain peptides can worsen. Address the underlying cause first. Reduce alcohol intake to zero, eliminate processed seed oils, increase daily steps to 8,000+, and retest in 6–8 weeks. If enzymes remain elevated, consult a hepatologist before considering peptides. Layering metabolic stressors on an already-stressed liver accelerates dysfunction rather than improving it.

What If My Testosterone Drops 30% After 12 Weeks on Peptides?

Certain peptides. Particularly those influencing the hypothalamic-pituitary-gonadal axis. Can suppress endogenous testosterone production. A 30% drop (e.g., 600 ng/dL to 420 ng/dL) is clinically significant even if levels remain within the reference range. Discontinue the peptide and retest in 4 weeks; most suppression reverses within 6–8 weeks post-discontinuation. If you're using growth hormone secretagogues alongside other compounds, the interaction may be synergistic. Isolate variables by removing one compound at a time and retesting.

The Unvarnished Truth About Adamax Blood Work Labs

Here's the honest answer: most people using peptides never get post-protocol blood work done, and most of those who do order the wrong panels. They test total testosterone but skip SHBG and free testosterone. They check fasting glucose but ignore fasting insulin and hemoglobin A1c. They assume "feeling fine" means the protocol is working optimally, when in reality IGF-1 could be climbing into ranges that increase cancer risk over decades, or liver enzymes could be creeping upward without symptoms.

Peptide protocols are not supplements. They are biochemical interventions with measurable physiological effects that extend far beyond what subjective assessment can detect. The Adamax blood work labs framework exists because symptom-free doesn't mean risk-free. You can feel excellent while developing insulin resistance, hepatic stress, or hormone suppression that will only become symptomatic years later. Post-protocol testing is the only way to confirm efficacy and detect risk before it compounds.

The research-grade peptides available through Real Peptides are manufactured to exact specifications for scientific study. They produce the effects they're designed to produce. That's precisely why monitoring matters. A high-purity peptide will elevate IGF-1 predictably, shift glucose metabolism measurably, and modulate hormone pathways detectably. Those effects can be beneficial or detrimental depending on dose, duration, and individual response. Blood work is the feedback loop that keeps the intervention therapeutic rather than reckless.

Most peptide-related problems aren't caused by impure compounds or incorrect dosing. They're caused by blind escalation without data. The protocol that works brilliantly for 8 weeks can become counterproductive at week 12 if IGF-1 overshoots or glucose regulation deteriorates. Without serial testing, you're optimizing based on how you feel, which lags behind biochemical reality by weeks or months. Serial Adamax blood work panels. Baseline, 8 weeks, 12 weeks, and every 12 weeks thereafter during active protocols. Provide the data required to dose intelligently rather than intuitively.

Frequently Asked Questions

Before starting any peptide protocol, obtain a comprehensive panel including complete metabolic panel (CMP), lipid panel (total cholesterol, LDL, HDL, triglycerides), complete blood count (CBC), thyroid function tests (TSH, Free T3, Free T4), hormone markers (total testosterone, free testosterone, estradiol, SHBG), IGF-1, fasting insulin, hemoglobin A1c, and liver enzymes (ALT, AST). Standard wellness panels often exclude IGF-1 and SHBG, so request these specifically.

Follow-up blood work should be conducted 8–12 weeks after initiating a peptide protocol to capture steady-state changes in hormonal and metabolic markers. IGF-1 typically reaches peak elevation within 4–8 weeks of starting growth hormone secretagogues; glucose and lipid changes manifest over 8–12 weeks. Testing earlier than 8 weeks may show transitional values that don’t reflect stable adaptation.

No — do not start peptide protocols if ALT exceeds 40 U/L or AST exceeds 35 U/L. Elevated liver enzymes indicate hepatic inflammation or stress, which certain peptides can worsen. Address the underlying cause (reduce alcohol, eliminate processed oils, increase activity) and retest in 6–8 weeks. Only consider peptides after liver function normalizes.

IGF-1 levels above 400 ng/mL indicate excessive dosing for most adults and increase risk of insulin resistance, joint pain, and long-term proliferative effects without proportional benefit. Therapeutic effects plateau at 40–90% elevation from baseline — if your baseline IGF-1 was 200 ng/mL, a post-protocol level of 280–380 ng/mL is optimal. Exceeding 400 ng/mL warrants immediate dose reduction by 30–50%.

Comprehensive Adamax blood work panels including IGF-1, hormone markers, metabolic function, and lipid profiles typically cost $250–$450 through direct-to-consumer lab services or $150–$300 if ordered through a physician and processed by a major lab network. Insurance rarely covers peptide-related monitoring unless tied to a diagnosed endocrine disorder.

A significant drop in testosterone (>20% from baseline) while using peptides suggests suppression of endogenous production, most commonly seen with compounds affecting the hypothalamic-pituitary-gonadal axis. Discontinue the peptide and retest in 4 weeks — most suppression reverses within 6–8 weeks. If testosterone remains suppressed, the protocol may require post-cycle hormone restoration.

Yes — SHBG (sex hormone-binding globulin) determines how much testosterone and estradiol are bioavailable versus protein-bound. Total testosterone can remain stable while SHBG shifts significantly, altering free hormone levels and symptom presentation. Changes in SHBG of 20% or more affect bioavailable testosterone enough to produce clinical effects even when total levels appear normal.

Yes — fasting glucose is a lagging indicator of glucose dysregulation. Fasting insulin and HOMA-IR (calculated from glucose and insulin) reveal insulin resistance earlier than glucose alone. Growth hormone and IGF-1 can induce compensatory hyperinsulinemia (elevated insulin with normal glucose) for months before fasting glucose rises. Monitor all three markers — glucose, insulin, and hemoglobin A1c — to catch metabolic shifts early.

Neuropeptides like Cerebrolysin don’t produce direct blood biomarkers the way growth hormone secretagogues elevate IGF-1, but indirect markers include cortisol (should normalize if previously elevated), TSH and thyroid hormones (cognitive peptides can shift thyroid function), and inflammatory markers like hs-CRP (should decrease with neuroregenerative support). Efficacy is primarily assessed through cognitive testing rather than blood work.

After the initial 8–12 week post-protocol panel, repeat comprehensive blood work every 12 weeks during active peptide use. If any marker shows concerning trends (rising glucose, elevated liver enzymes, shifting hormone ratios), retest that specific marker at 4–6 week intervals until it stabilizes. Annual comprehensive panels are insufficient for peptide monitoring — metabolic changes can occur within 8–12 weeks.